<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689142</url>
  </required_header>
  <id_info>
    <org_study_id>EFC12512</org_study_id>
    <secondary_id>U1111-1130-3649</secondary_id>
    <nct_id>NCT01689142</nct_id>
  </id_info>
  <brief_title>Comparison of a New Formulation of Insulin Glargine With Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
  <acronym>EDITION JP II</acronym>
  <official_title>A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Both in Combination With Oral Antihyperglycemic Drug(s) in Japanese Patients With Type 2 Diabetes Mellitus With a 6 Month Safety Extension Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

      To compare the efficacy of a new formulation of insulin glargine and Lantus in terms of
      change of HbA1c from baseline to endpoint (scheduled at month 6 [week 26]) in japanese
      patients with type 2 diabetes mellitus.

      Secondary Objectives:

      To compare a new formulation of insulin glargine and Lantus in terms of change in fasting
      plasma glucose (FPG), preinjection plasma glucose, 8-point self-measured plasma glucose
      (SMPG) profile.

      To compare a new formulation of insulin glargine and Lantus in terms of occurrence of
      hypoglycemia
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The duration of study will consist of:

        -  Up to 2-week screening period;

        -  6-month open-label comparative efficacy and safety treatment period;

        -  6-month open-label comparative safety extension period;

        -  4-week post-treatment safety follow-up period
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in HbA1c</measure>
    <time_frame>baseline, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of HbA1c responders (HbA1c &lt; 7%; &lt; 6.5%)</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in FPG</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in pre-basal insulin injection SMPG</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 8-point SMPG profiles</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24-hour mean plasma glucose of SMPG profiles (mean of 8-point values)</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in variability of plasma glucose profile</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in daily basal insulin dose</measure>
    <time_frame>baseline, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with various types of hypoglycemia events</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>New formulation of insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>once daily in the evening on-top of oral antihyperglycemic drug (OADs)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lantus (insulin glargine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily in the evening on-top of OADs</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine new formulation (HOE901)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: subcutaneous</description>
    <arm_group_label>New formulation of insulin glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin glargine (HOE901)</intervention_name>
    <description>Pharmaceutical form: solution Route of administration: subcutaneous</description>
    <arm_group_label>Lantus (insulin glargine)</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :

        o Patients with type 2 diabetes mellitus diagnosed for at least 1 year at the time of
        screening visit treated with basal insulin in combination with oral antihyperglycemic drugs
        (OADs) for at least 6 months before screening visit;

        Exclusion criteria:

          -  Age &lt; 18 years at screening visit;

          -  BMI(body mass index) ≥ 35 kg/m2 at screening visit;

          -  HbA1c &lt; 7.0% or &gt; 10% (national glycohemoglobin standardization program [NGSP] value)
             at screening visit;

          -  Diabetes other than type 2 diabetes mellitus;

          -  Patients on self-monitoring of blood glucose less than 6 months before screening
             visit;

          -  Patients using pre-mix insulins, insulin detemir at 2 times or more a day, or GLP 1
             receptor agonists in the last 3 months before screening visit;

          -  Patients using mealtime insulin (rapid-acting insulin analogue and short-acting
             insulin) for more than 10 days in the last 3 months before screening visit;

          -  Use of insulin pump in the last 6 months before screening visit;

          -  Initiation of new glucose-lowering medications and/or weight loss drugs in the last 3
             months before screening visit;

          -  Severe hypoglycemia resulting in coma/seizures, and/or hospitalization for diabetic
             ketoacidosis in the last 6 months before screening visit;

          -  Unstable proliferative diabetic retinopathy or any other rapidly progressive diabetic
             retinopathy or macular edema likely to require treatment (eg, laser, surgical
             treatment or injectable drugs) during the study period.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number 392226</name>
      <address>
        <city>Amagasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392218</name>
      <address>
        <city>Chigasaki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392212</name>
      <address>
        <city>Chiyoda-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392209</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392210</name>
      <address>
        <city>Chuo-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392208</name>
      <address>
        <city>Chuoh-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392217</name>
      <address>
        <city>Ebina-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392216</name>
      <address>
        <city>Fujisawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392222</name>
      <address>
        <city>Higashiosaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392223</name>
      <address>
        <city>Izumisano-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392215</name>
      <address>
        <city>Kamakura-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392225</name>
      <address>
        <city>Kashiwara-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392205</name>
      <address>
        <city>Kawagoe-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392204</name>
      <address>
        <city>Kawaguchi-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392206</name>
      <address>
        <city>Kisarazu-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392201</name>
      <address>
        <city>Koriyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392228</name>
      <address>
        <city>Kurashiki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392229</name>
      <address>
        <city>Matsuyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392230</name>
      <address>
        <city>Matsuyama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392211</name>
      <address>
        <city>Mitaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392220</name>
      <address>
        <city>Nagoya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392227</name>
      <address>
        <city>Nishinomiya-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392203</name>
      <address>
        <city>Ogawa-Machi, Hikigun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392231</name>
      <address>
        <city>Okawa-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392224</name>
      <address>
        <city>Osaka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392207</name>
      <address>
        <city>Shinjuku-Ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392219</name>
      <address>
        <city>Shizuoka-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392221</name>
      <address>
        <city>Takatsuki-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392202</name>
      <address>
        <city>Ushiku-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392213</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 392214</name>
      <address>
        <city>Yokohama-Shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>June 4, 2014</last_update_submitted>
  <last_update_submitted_qc>June 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

